冠心病患者PCI术后LOX-1变化在社区综合管理中的作用  

Role of LOX-1 changes in coronary heart disease patients after PCI in the community comprehensive management

作　　者：薛红梅 陆军[1] 张庆勇 XUE Hongmei;LU Jun;ZHANG Qingyong(General Practice Clinic of Huajing Community Health Service Center of Xuhui District,Shanghai 200231,China;Department of Cardiovascular Internal Medicine of Shanghai 9th People’s Hospital,Shanghai 200011,China)

机构地区：[1]上海市徐汇区华泾镇社区卫生服务中心全科门诊,上海200231 [2]上海市第九人民医院心血管内科,上海200011

出　　处：《上海医药》2024年第10期47-50,共4页Shanghai Medical & Pharmaceutical Journal

基　　金：徐汇区医学科研项目(SHXH202021)。

摘　　要：目的:分析冠心病(CHD)患者经皮冠状动脉介入(PCI)术后6个月和12个月凝集素样氧化型低密度脂蛋白受体1(LOX-1)的动态变化情况,评估综合管理康复治疗的疗效。方法:收集2021年1月至2022年12月门诊60例冠心病患者PCI治疗前和治疗后6个月和12个月的血清样本。患者平均年龄59.4岁,被分为对照组和干预组,每组30例。对照组中男性14例,女性16例;干预组中男性17例,女性13例。采用酶联免疫吸附测定方法检测LOX-1含量,并统计主要心脏不良事件(MACE)发生率。结果:干预组在6个月和12个月时LOX-1水平显著低于对照组以及术前水平,差异均有统计学意义(均P<0.05),且在6个月时效果最为显著。12个月时干预组患者的MACE发生率明显低于对照组,且对照组与干预组中无MACE患者的LOX-1水平显著低于有MACE的患者。结论:LOX-1的水平与CHD患者PCI术后及远期MACE发生率密切相关,社区综合管理需要加强LOX-1的干预,减少MACE的发生,因此LOX-1的动态水平可作为综合管理康复治疗疗效评估指标之一。Objective:To analyze the dynamic changes of lectin-like oxidized low-density lipoprotein receptor-1(LOX-1)at 6 and 12 months after percutaneous coronary intervention(PCI)in patients with coronary heart disease(CHD),and to evaluate the efficacy of comprehensive management of rehabilitation.Methods:Serum samples of 60 CHD patients in the clinic from January 2021 to December 2022 were collected before treatment and 6 and 12 months after treatment.The average age of the patients was 59.4 years old,and they were divided into a control group and an intervention group with 30 cases each.In the control group there were 14 males and 16 females;in the intervention group there were 17 males and 13 females.Enzyme-linked immunosorbent assay was used to detect the content of LOX-1 and the incidence of major adverse cardiac events(MACE)was also calculated.Results:LOX-1 level was significantly lower in the intervention group at 6 and 12 months than that in the control group and before surgery,and the difference was statistically significant(P<0.05),and the effect was most significant at 6 months.At 12 months,the incidence of MACE in the intervention group was significantly lower than that in the control group,and LOX-1 level in the patients without MACE was significantly lower than that in the patients with MACE in the both control and intervention groups.Conclusion:The level of LOX-1 is closely related to the incidence of MACE in patients with CHD after PCI and in the long term,community comprehensive management needs to be strengthened the intervention of LOX-1 to reduce the incidence of MACE.Therefore,the dynamic level of LOX-1 can be used as one of the evaluation indexes of the efficacy of comprehensive management rehabilitation therapy.

关 键 词：冠心病 经皮冠状动脉介入术 凝集素样氧化型低密度脂蛋白受体 主要心脏不良事件 

分 类 号：R541.4[医药卫生—心血管疾病]